Aligos Therapeutics Reports Positive 96-Week Data for Pevifoscorvir Sodium in Chronic Hepatitis B
Aligos Therapeutics Inc. reported positive 96-week data for pevifoscorvir sodium, a treatment for chronic hepatitis B, at The Liver Meeting® 2025. The results indicated effective suppression of HBV DNA and reduced HBV antigen levels in treatment-naive subjects. Presentations included an oral report by Professor Man-Fung Yuen and preclinical data on ALG-001075, which inhibits cccDNA formation. The company also noted advancements in its HBV antisense oligonucleotide program.
Aligos Therapeutics Inc. announced positive data from multiple presentations at the American Association for the Study of Liver Disease’s The Liver Meeting® 2025, held November 7-11, 2025, in Washington, D.C. The company highlighted clinical results for pevifoscorvir sodium, a capsid assembly modulator under investigation for the treatment of chronic hepatitis B virus (HBV) infection. An oral presentation and several posters detailed 96-week treatment and post-treatment data, suggesting pevifoscorvir sodium demonstrates potent suppression of HBV DNA and sustained reduction of HBV antigen levels in treatment-naive or currently-not-treated subjects. The results were presented by Professor Man-Fung Yuen of the University of Hong Kong. Aligos also presented preclinical data on other investigational agents, including the capsid assembly modulator ALG-001075, which prevents cccDNA formation and HBV DNA integration in vitro. The company indicated ongoing progress in its HBV antisense oligonucleotide (ASO) program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571440-en) on November 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
